- $105.73m
- $94.72m
- 31
- 14
- 85
- 38
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 10.18 | ||
| Price to Tang. Book | 10.18 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -83.3% | ||
| Return on Equity | -80.3% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.24 | 0.36 | 0.57 | 0.13 | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.
Directors
- Gerald Lieberman NEC (74)
- Spiros Jamas CEO (60)
- Phillip Schwartz CEX (59)
- Hillel Galitzer COO (42)
- Ramesh Ratan OTH
- Arthur Santora OTH (70)
- Dana Yaacov-Garbeli OTH (37)
- Zeev Bronfeld DRC (70)
- Sean Ellis DRC (46)
- Roger Garceau DRC (67)
- Yonatan Malca DRC (55)
- Ron Mayron DRC (58)
- Faith Charles IND (59)
- Gerald Ostrov IND (71)
- Miranda Toledano IND (44)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 30th, 2009
- Public Since
- June 28th, 2018
- No. of Shareholders
- 89
- No. of Employees
- 17
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 35,481,341
- Address
- Hadassah / Jerusalem Bio, JERUSALEM, 9112002
- Web
- https://enterabio.com/
- Phone
- +972 25327151
- Auditors
- Kesselman & Kesselman
Upcoming Events for ENTX
Q2 2024 Entera Bio Ltd Earnings Release
Entera Bio Ltd Annual Shareholders Meeting
Similar to ENTX
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Entera Bio share price?
As of Today at 19:07 UTC, shares in Entera Bio are trading at $2.98. This share price information is delayed by 15 minutes.
How has the Entera Bio share price performed this year?
Shares in Entera Bio last closed at $2.98 and the price had moved by +231.11% over the past 365 days. In terms of relative price strength the Entera Bio share price has outperformed the S&P500 Index by +167.4% over the past year.
What are the analyst and broker recommendations for Entera Bio?
The overall consensus recommendation for Entera Bio is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Entera Bio dividend yield?
Entera Bio does not currently pay a dividend.
Does Entera Bio pay a dividend?
Entera Bio does not currently pay a dividend.
When does Entera Bio next pay dividends?
Entera Bio does not currently pay a dividend.
How do I buy Entera Bio shares?
To buy shares in Entera Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Entera Bio?
As of the previous close price of $2.98, shares in Entera Bio had a market capitalisation of $105.73m.
Where are Entera Bio shares listed?
Here are the trading details for Entera Bio:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ENTX
What kind of share is Entera Bio?
Based on an overall assessment of its quality, value and momentum Entera Bio is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Entera Bio share price forecast for 2024?
The analyst consensus target price for shares in Entera Bio is $10.00. That is 235.57% above the last closing price of $2.98.
Analysts covering Entera Bio currently have a consensus Earnings Per Share (EPS) forecast of -$0.25 for the next financial year.
What is the trend in the Entera Bio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Entera Bio. Over the past six months, its share price has outperformed the S&P500 Index by +248.48%.
As of the last closing price of $2.98, shares in Entera Bio were trading +229.98% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Entera Bio PE Ratio?
The Entera Bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.98.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Entera Bio?
Entera Bio's management team is headed by:
- Gerald Lieberman - NEC
- Spiros Jamas - CEO
- Phillip Schwartz - CEX
- Hillel Galitzer - COO
- Ramesh Ratan - OTH
- Arthur Santora - OTH
- Dana Yaacov-Garbeli - OTH
- Zeev Bronfeld - DRC
- Sean Ellis - DRC
- Roger Garceau - DRC
- Yonatan Malca - DRC
- Ron Mayron - DRC
- Faith Charles - IND
- Gerald Ostrov - IND
- Miranda Toledano - IND